Revenue of the RNA Targeting Small Molecule Drug Discovery Market Predicted to Achieve $6.04 Billion by 2030, Driven by 23.5% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the rna targeting small molecule drug discovery market from 2026–2035 with trusted insights from The Business Research Company
How much larger will the RNA Targeting Small Molecule Drug Discovery Market be in 2030 compared with 2026?
The rna targeting small molecule drug discovery market has witnessed significant expansion over recent years. It is projected to increase from $2.13 billion in 2025 to $2.6 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.3%. This historical growth can be attributed to several factors including the constrained druggability of protein targets, the increasing occurrence of genetic disorders, breakthroughs in rna biology research, an escalation in academic-industry partnerships, and the initial successful outcomes of rna-based therapeutics.
The rna targeting small molecule drug discovery market is projected for rapid expansion in the coming years, reaching $6.04 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 23.5%. This projected growth during the forecast period is fueled by several factors, including AI-enabled rna target identification, rising investments in precision medicine, the broadening of rna therapeutics pipelines, advancements in rna delivery technologies, and favorable regulatory backing for new modalities. Key trends anticipated over the forecast period encompass AI-driven rna structure prediction, the expansion of rna-targeted oncology pipelines, developments in rna-specific small molecule libraries, enhanced rna binding selectivity and specificity, and the incorporation of multi-omics approaches within rna drug discovery.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp
What Drivers Are Guiding Growth Patterns In The RNA Targeting Small Molecule Drug Discovery Market?
The RNA-targeted small-molecule drug discovery market is projected to expand due to the rising occurrence of cancer, genetic disorders, and viral infections. Cancer involves the uncontrolled proliferation of cells within the body. Viral infections are conditions resulting from viruses, which are minute infectious agents capable of replication only within living organism cells. RNA targeting-based drug discovery provides therapeutic solutions for cancer, genetic disorders, and viral infections because these conditions are associated with genes and dysfunctional genetic material, which can be addressed by medications developed through RNA targeting approaches. As an illustration, a report released in February 2024 by the World Health Organization (WHO), a Switzerland-based intergovernmental body, estimated 20 million new cancer cases and 9.7 million deaths worldwide in 2022. Lung cancer represented the highest incidence with 2.5 million new cases (12.4%), succeeded by female breast cancer at 2.3 million cases (11.6%), colorectal cancer at 1.9 million cases (9.6%), prostate cancer at 1.5 million cases (7.3%), and stomach cancer at 970,000 cases (4.9%). Projections indicate that by 2050, the number of new cancer cases will escalate by 77%, surpassing 35 million each year. Consequently, the rising occurrence of cancer, genetic disorders, and viral infections fuels the expansion of the RNA-targeted small-molecule drug discovery market.
Which Segments Are Driving Activity In The RNA Targeting Small Molecule Drug Discovery Market?
The rna targeting small molecule drug discovery market covered in this report is segmented –
1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods
4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications
Subsegments:
1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition
2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA
3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways
4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA
Which Trends Are Influencing The Performance And Direction Of The RNA Targeting Small Molecule Drug Discovery Market?
Prominent entities within the RNA-targeting small-molecule drug discovery market are implementing advanced platforms, including software-as-a-service (SaaS) models, to achieve a competitive advantage. SaaS functions as a software delivery system, wherein external providers host applications, making them accessible to users via the internet. An example of this is the launch of AIDDISSON by Merck & Co. Inc., a US-based science and technology firm, in December 2023. This platform provides recommendations for the optimal synthesis pathways of selected medications. Such an innovative methodology promises substantial cost reductions in drug discovery and considerably improves the success rate of bringing new drugs to patients. Moreover, by connecting virtual molecular design with practical manufacturing capabilities, the platform enhances the likelihood of delivering innovative treatments to patients, achieving this by uncovering valuable insights from vast datasets. This new AI system amalgamates computer-aided drug design, machine learning, and generative AI to expedite the overall medication development timeline.
Which Leading Companies Dominate The RNA Targeting Small Molecule Drug Discovery Market Share?
Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation
Access The Complete Report For Deeper Market Insights:
How Does The RNA Targeting Small Molecule Drug Discovery Market Perform Across Major Global Regions?
North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized RNA Targeting Small Molecule Drug Discovery Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp
Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2026, By The Business Research Company
Rna Targeting Small Molecule Drug Discovery Market Report 2026
Rna Targeting Small Molecules Therapeutics Market Report 2026
Small Molecule Drug Discovery Market Report 2026
https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
